RED BANK, NJ--(Marketwire - Feb 15, 2012) - TGI SOLAR POWER GROUP INC. (PINKSHEETS: [ TSPG ]) ([ www.tgisolar.com ]) a diversified energy company, is pleased to announce that after close to twelve months of negotiations, it has finalized an Agreement with Olagenesis Corp ([ http://www.olagenesis.com ]). The Agreement calls for Olagenesis to assign its license and rights it acquired from Medizinische Hochschule Hannover, a non-profit research and teaching institution located in Hannover, Germany to NANOREGEN in exchange of consideration.

TGI has retained law firm GUZOV OFSINK, LLC ([ www.golawintl.com ]) to assist with completion of this transaction.

About Olagenesis

Olagenesis Corp. is developing Bone Marrow Mononuclear Cell (BMCC) transplant therapy for the treatment of severe acute and chronic cardiac disease, and has secured worldwide commercialization rights from the University of Hannover, Hannover, Germany to use BMCCs for such indications. Olagenesis is planning international, multi-center phase III clinical trials for the use of BMCCs to treat severe acute myocardial infarction. Phase II clinical studies have been successfully completed by the University of Hannover.

About TGI Solar

TGI SOLAR POWER GROUP INC. ([ www.tgisolar.com ]) is a diversified holding company. The Company offers its products and services to clients on a worldwide basis and currently maintains JVs and strategic alliances with installation, integration and energy consulting firms. TGI's strategy is to acquire new patented technologies, components, processes, designs and methods with commercial value that will give market advantage and generate shareholder value.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.